MannKind saw decent growth from its two core products in Q2 and just signed a new non-dilutive financing agreement with ...

MannKind Corporation (NASDAQ:MNKD) presented inhaled insulin therapy at the American Diabetes Association’s 85th Scientific Sessions in Chicago, which was held from June 20 to June 23, 2025.

The Brain Computer Interface Market was valued at USD 1.6 billion in 2024 and is projected to reach USD 6.3 billion by 2033, ...

MannKind Corporation (NASDAQ:MNKD) is one of the High Growth Penny Stocks That Are Profitable in 2025. On July 23, RBC ...

MannKind Corporation (NASDAQ:MNKD) presented inhaled insulin therapy at the American Diabetes Association’s 85th Scientific Sessions in Chicago, which was held from June 20 to June 23, 2025.

During the fiscal first quarter of 2025, the company noted that its Afrezza, an inhaled insulin, saw 20% new prescription growth and 14% total prescription growth year-over-year.

Ultra-rapid insulins are used to manage type 1 and type 2 diabetes. Learn about the different types, their effectiveness, and how they can provide mealtime flexibility.

The company submitted its lead inhaled insulin product for expanded FDA approval and secured $500 million in funding, it said ...

Good morning, and welcome to the MannKind Corporation Second Quarter 2025 Financial Results Conference Call. As a reminder, this call is being recorded on August 6, 2025, and will be available for ...

The study focuses on the efficacy and safety of Afrezza, an inhaled insulin powder for children with Type 1 diabetes.